Study guide

11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders

NPLEX Part I — Biomedical Sciences Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Pacing, and GEA Strategy

1.1 Overview of NPLEX Part I & NABNE Exam Structure 1.2 Deconstructing Biomedical Clinical Vignettes 1.3 General Exam Areas (GEAs) & Passing Standards

2 Chapter 2: Gross Anatomy & Musculoskeletal System

2.1 Musculoskeletal Anatomy of Upper and Lower Extremities 2.2 Structural Anatomy of Head, Neck, Thorax, and Abdomen 2.3 Pelvic Architecture, Perineal Anatomy, and Articular Structures

3 Chapter 3: Histology & Microscopic Anatomy

3.1 Histology of Epithelial, Connective, and Muscular Tissues 3.2 Microscopic Structure of Gastrointestinal, Renal, and Endocrine Organs 3.3 Microscopic Anatomy of Integument, Lymphoid Tissues, and Respiratory Epithelium

4 Chapter 4: Neuroanatomy & Special Senses

4.1 Cranial Nerves, Nuclei, and Peripheral Distribution 4.2 Spinal Cord Tracts, Brainstem Circuits, and Motor/Sensory Pathways 4.3 Cerebral Cortex, Basal Ganglia, Limbic System, and Autonomic Nervous System 4.4 Neuroanatomy of Vision, Audition, Vestibular Function, and Olfaction/Gustation

5 Chapter 5: Embryology & Developmental Anatomy

5.1 Gametogenesis, Fertilization, Blastulation, and Germ Layer Derivatives 5.2 Organogenesis: Cardiovascular and Respiratory System Development 5.3 Gastrointestinal, Urogenital, and Craniofacial Embryology

6 Chapter 6: Cellular & General Physiology

6.1 Membrane Transport Mechanics, Resting Potentials, and Ion Channels 6.2 Action Potential Propagation and Synaptic Transmission 6.3 Excitation-Contraction Coupling in Skeletal, Cardiac, and Smooth Muscle

7 Chapter 7: Cardiovascular & Respiratory Physiology

7.1 Cardiac Electrophysiology, ECG, and Mechanical Cardiac Cycle 7.2 Hemodynamics, Peripheral Resistance, and Blood Pressure Control 7.3 Pulmonary Mechanics, Lung Volumes, and Gas Exchange Dynamics 7.4 Transport of Oxygen/CO2 and Neural/Chemical Control of Breathing

8 Chapter 8: Renal, Fluid, & Acid-Base Physiology

8.1 Glomerular Filtration Rate and Tubular Reabsorption/Secretion Mechanics 8.2 Countercurrent Multiplication, Osmoregulation, and Urine Concentration 8.3 Body Fluid Compartments, Sodium/Water Homeostasis, and Potassium Dynamics 8.4 Renal & Respiratory Acid-Base Regulation and Compensation Mechanisms

9 Chapter 9: Gastrointestinal, Endocrine, & Reproductive Physiology

9.1 GI Motility, Secretory Functions, Digestion, and Nutrient Absorption 9.2 Hypothalamic-Pituitary Axes, Adrenal Gland, and Thyroid Physiology 9.3 Endocrine Pancreas, Glucose Regulation, Calcium/Phosphate Homeostasis 9.4 Male and Female Reproductive Endocrinology and Menstrual Cycle Regulation

10 Chapter 10: Enzymology, Bioenergetics, & Carbohydrate/Lipid Metabolism

10.1 Enzyme Kinetics, Catalytic Mechanisms, and Vitamin Cofactors 10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation 10.3 Glycogen Metabolism, Gluconeogenesis, and Pentose Phosphate Pathway 10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport

11 Chapter 11: Amino Acid/Nucleotide Metabolism & Clinical Genetics

11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders 11.2 Purine and Pyrimidine Synthesis, Salvage, and Gout Pathophysiology 11.3 Mendelian Inheritance, Chromosomal Abnormalities, and Molecular Genetics

12 Chapter 12: Immunology & Immunopathology

12.1 Innate Immune Barriers, Phagocytosis, Cellular Pattern Recognition, and Complement System 12.2 Adaptive Immunity: T-Cell & B-Cell Activation, MHC Restriction, and Antibodies 12.3 Types I-IV Hypersensitivity Reactions and Mechanisms of Autoimmunity 12.4 Immunodeficiency Syndromes, Tumor/Transplant Immunology, and Vaccine Types

13 Chapter 13: Medical Microbiology

13.1 Medical Bacteriology: Gram-Positive, Gram-Negative, and Atypical Bacteria 13.2 Medical Virology: DNA, RNA, Retroviruses, and Viral Pathogenesis 13.3 Medical Mycology: Cutaneous, Systemic, and Opportunistic Fungal Infections 13.4 Medical Parasitology: Protozoan and Helminthic Pathogens

14 Chapter 14: General Pathology & Neoplasia

14.1 Cellular Adaptation, Reversible/Irreversible Injury, Necrosis, and Apoptosis 14.2 Acute and Chronic Inflammation, Chemical Mediators, and Tissue Healing 14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors

15 Chapter 15: Systems Pathology & Disease Mechanisms

15.1 Pathophysiology of Atherosclerosis, Heart Failure, COPD, and Pneumonias 15.2 Glomerulonephritis, Inflammatory Bowel Disease, and Hepatorenal Disease Pathophysiology 15.3 Endocrine Disorders, Neurodegenerative Pathology, and Epidemiological Principles 15.4 Hematopoietic System Pathology: Anemias, Coagulopathies, and Hematologic Neoplasms 15.5 Immunological System Pathology: Autoimmune, Amyloid, and Systemic Immune-Mediated Disease 15.6 Integumentary System Pathology: Inflammatory Dermatoses, Blistering Disorders, and Skin Neoplasms 15.7 Musculoskeletal System Pathology: Metabolic Bone Disease, Arthropathies, and Bone Neoplasms 15.8 Reproductive System Pathology: Endocrine, Inflammatory, and Neoplastic Disorders of the Reproductive Tract

11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders

Key Takeaways Explain This Topic AI

Transamination reactions transfer amino groups to alpha-ketoglutarate forming glutamate, strictly requiring Pyridoxal Phosphate (PLP, Vitamin B6) as an essential cofactor.

Glutamate dehydrogenase releases free ammonium in the mitochondrial matrix, which enters the rate-limiting step of the Urea Cycle catalyzed by Carbamoyl Phosphate Synthetase I (CPS-I), activated obligately by N-acetylglutamate (NAG).

Ornithine Transcarbamylase (OTC) deficiency is X-linked recessive and causes hyperammonemia with urine orotic acid but NO megaloblastic anemia.

Inborn errors of amino acid catabolism present distinct clinical signs: PKU (PAH deficiency, musty odor, hypopigmentation), Alkaptonuria (homogentisate oxidase deficiency, black urine, ochronosis), Homocystinuria (CBS deficiency, marfanoid habitus, downward lens subluxation, thrombosis), and MSUD (BCKDH deficiency, sweet maple syrup odor).

Last updated: July 2026

11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders

Amino acid metabolism represents a central pillar of human biochemistry, orchestrating both the synthesis of crucial proteins and nitrogenous compounds and the catabolism of excess amino acids. Unlike carbohydrates and lipids, surplus amino acids cannot be stored in human tissues; excess amino acids are degraded, with their carbon skeletons entering gluconeogenesis or the citric acid cycle while their toxic amino groups ( N H 3 / N H 4 + NH_3/NH_4^+ N H 3 ​ / N H 4 + ​ ) are processed and safely excreted as urea. Understanding the pathways of transamination, oxidative deamination, urea synthesis, and the inherited metabolic defects resulting from specific enzymatic deficiencies is essential for NPLEX Part I preparation and clinical naturopathic practice.

Transamination & Oxidative Deamination

The initial step in the catabolism of most L-amino acids involves transamination , the enzymatic transfer of an α \alpha α -amino group from an amino acid to an α \alpha α -keto acid acceptor, primarily α \alpha α -ketoglutarate. This reaction generates a new α \alpha α -keto acid (corresponding to the carbon skeleton of the original amino acid) and L-glutamate.

Transamination reactions are catalyzed by aminotransferases (also called transaminases), with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serving as prime clinical biomarkers:

ALT transfers the amino group of alanine to α \alpha α -ketoglutarate, forming pyruvate and glutamate ( A l a n i n e + α -Ketoglutarate ⇌ P y r u v a t e + G l u t a m a t e Alanine + \alpha\text{-Ketoglutarate} \rightleftharpoons Pyruvate + Glutamate A l anin e + α -Ketoglutarate ⇌ P yr uv a t e + Gl u t ama t e ).

AST transfers the amino group of aspartate to α \alpha α -ketoglutarate, forming oxaloacetate and glutamate ( A s p a r t a t e + α -Ketoglutarate ⇌ O x a l o a c e t a t e + G l u t a m a t e Aspartate + \alpha\text{-Ketoglutarate} \rightleftharpoons Oxaloacetate + Glutamate A s p a r t a t e + α -Ketoglutarate ⇌ O x a l o a ce t a t e + Gl u t ama t e ).

All transaminases strictly require pyridoxal phosphate (PLP) , the active coenzyme form of vitamin B6 , as an essential prosthetic group. PLP acts as an intermediate amino carrier during the ping-pong kinetic mechanism. Consequently, vitamin B6 deficiency impairs amino acid degradation and neurotransmitter synthesis.

Following transamination, nitrogen collected in glutamate enters oxidative deamination within the mitochondrial matrix of hepatocytes. This reaction is catalyzed by glutamate dehydrogenase (GDH) , an enzyme unique in its capacity to utilize either N A D + NAD^+ N A D + or N A D P + NADP^+ N A D P + as an electron acceptor: Glutamate + N A D ( P ) + + H 2 O ⇌ α -Ketoglutarate + N A D ( P ) H + H + + N H 4 + \text{Glutamate} + NAD(P)^+ + H_2O \rightleftharpoons \alpha\text{-Ketoglutarate} + NAD(P)H + H^+ + NH_4^+ Glutamate + N A D ( P ) + + H 2 ​ O ⇌ α -Ketoglutarate + N A D ( P ) H + H + + N H 4 + ​

GDH releases free ammonium ( N H 4 + NH_4^+ N H 4 + ​ ) for urea synthesis while regenerating α \alpha α -ketoglutarate. GDH is allosterically regulated: high energy levels (ATP and GTP) inhibit GDH, whereas low energy states (ADP and GDP) activate it to drive carbon skeleton oxidation.

Nitrogen generated in extrahepatic peripheral tissues cannot travel through circulation as toxic free ammonia. Instead, peripheral nitrogen is safely transported to the liver primarily as glutamine (catalyzed by mitochondrial glutamine synthetase ) or as alanine via the glucose-alanine cycle (Cahill cycle) from skeletal muscle. In the liver, hepatic glutaminase cleaves glutamine to yield glutamate and free N H 4 + NH_4^+ N H 4 + ​ , feeding directly into the urea cycle.

The Urea Cycle: Enzymatic Steps & Regulation

The urea cycle (Krebs-Henseleit cycle) operates exclusively in hepatocytes, spanning both the mitochondrial matrix and the cytosol. It detoxifies toxic free ammonia into water-soluble urea , which is excreted by the kidneys.

The complete pathway involves five core enzymatic reactions. A classic medical mnemonic for the sequential nitrogenous intermediates is: "Lover Can Carefully Enter Secret Compartments" ( L-Ornithine, Carbamoyl phosphate, Citrulline, Argininosuccinate, Fumarate, Arginine, Urea ).

Mitochondrial Matrix Phase :

Step 1 (Rate-Limiting) : Free N H 4 + NH_4^+ N H 4 + ​ combines with C O 2 CO_2 C O 2 ​ (bicarbonate) and 2 molecules of ATP to form carbamoyl phosphate , catalyzed by Carbamoyl Phosphate Synthetase I (CPS-I) . CPS-I requires N-acetylglutamate (NAG) as an absolute obligate allosteric activator. NAG is synthesized from acetyl-CoA and glutamate by NAG synthase , an enzyme activated by high levels of arginine.

Step 2 : Carbamoyl phosphate condenses with L-ornithine to form citrulline , catalyzed by Ornithine Transcarbamylase (OTC) . Citrulline is transported across the inner mitochondrial membrane into the cytosol via specific transport proteins.

Cytosolic Phase :

Step 3 : Citrulline condenses with aspartate (providing the second nitrogen atom of urea) to form argininosuccinate , catalyzed by argininosuccinate synthetase (requires 1 ATP, cleaved to AMP + P P i PP_i P P i ​ , equivalent to 2 high-energy phosphate bonds).

Step 4 : Argininosuccinate lyase cleaves argininosuccinate into arginine and fumarate . Fumarate links the urea cycle to the citric acid cycle (gluconeogenesis).

Step 5 : Arginase hydrolyzes arginine to regenerate L-ornithine (which re-enters the mitochondrion) and release urea . Overall Reaction: N H 4 + + H C O 3 − + Aspartate + 3 ATP + H 2 O → Urea + Fumarate + 2 ADP + 2 P i + AMP + P P i \text{Overall Reaction: } NH_4^+ + HCO_3^- + \text{Aspartate} + 3\text{ ATP} + H_2O \rightarrow \text{Urea} + \text{Fumarate} + 2\text{ ADP} + 2\text{ P}_i + \text{AMP} + PP_i Overall Reaction: N H 4 + ​ + H C O 3 − ​ + Aspartate + 3 ATP + H 2 ​ O → Urea + Fumarate + 2 ADP + 2 P i ​ + AMP + P P i ​

Urea Cycle Disorders: OTC Deficiency

Enzyme deficiencies in the urea cycle lead to hyperammonemia , causing toxic accumulation of N H 3 NH_3 N H 3 ​ in the central nervous system. Ammonia depletes neuronal α \alpha α -ketoglutarate (inhibiting the TCA cycle) and increases brain glutamine, leading to astrocyte swelling and fatal cerebral edema.

Ornithine Transcarbamylase (OTC) Deficiency is the most common urea cycle disorder and the only one with X-linked recessive inheritance (all others are autosomal recessive).

Pathophysiology : Defective OTC prevents condensation of carbamoyl phosphate with ornithine in mitochondria. Excess carbamoyl phosphate leaks into the cytosol, where it enters the pyrimidine synthesis pathway, driving massive overproduction of orotic acid .

Clinical Presentation : Severe neonatal hyperammonemia, vomiting, lethargy, asterixis, tachypnea (from central hyperventilation), seizures, and coma.

Diagnostic Distinctions : Laboratory evaluation demonstrates elevated blood ammonia, low blood urea nitrogen (BUN), and marked orotic aciduria in urine. Crucially, OTC deficiency shows normal hematocrit without megaloblastic anemia . This sharply contrasts with UMP synthase deficiency (hereditary orotic aciduria), which also presents with urine orotic acid but exhibits megaloblastic anemia and normal ammonia levels.

Inherited Disorders of Amino Acid Catabolism

Defects in specific enzymes degrading amino acid carbon skeletons lead to distinct clinical disorders with metabolic toxicity:

1. Phenylketonuria (PKU)

Etiology : Autosomal recessive deficiency of phenylalanine hydroxylase (PAH) or its essential cofactor tetrahydrobiopterin ( B H 4 BH_4 B H 4 ​ ) . PAH converts phenylalanine to tyrosine.

Pathophysiology : Phenylalanine accumulates and is converted via alternative pathways into phenylketones (phenylpyruvate, phenyllactate, phenylacetate), which spill into urine. Tyrosine becomes an essential amino acid .

Clinical Manifestations : Untreated infants develop severe intellectual disability, microcephaly, seizures, growth failure, and a characteristic musty or mousy body odor . Due to impaired tyrosine production (and subsequent decreased melanin synthesis), patients exhibit hypopigmentation (fair skin, blonde hair, blue eyes).

Management : Immediate dietary restriction of phenylalanine (avoiding high-protein foods and aspartame) supplemented with synthetic tyrosine.

2. Alkaptonuria

Etiology : Autosomal recessive deficiency of homogentisate oxidase in the tyrosine degradation pathway.

Pathophysiology : Inability to degrade homogentisic acid leads to its accumulation and deposition in connective tissues.

Clinical Manifestations : Classic triad: dark or black urine upon standing (as homogentisic acid oxidizes in air), ochronosis (bluish-black pigmentation of the sclera, ear cartilage, and connective tissues), and severe, debilitating premature osteoarthritis (ochronotic arthropathy) occurring in early adulthood.

3. Homocystinuria

Etiology : Autosomal recessive deficiency of cystathionine β \beta β -synthase (CBS) (requiring B6), or deficiencies of methionine synthase (requiring B12) or methylenetetrahydrofolate reductase (MTHFR, requiring folate).

Pathophysiology : Accumulation of homocysteine and methionine with reduced cysteine production.

Clinical Manifestations : Marfanoid habitus (tall stature, long slender digits, pectus excavatum), downward and inward lens subluxation (ectopia lentis; contrast with Marfan syndrome which exhibits upward subluxation), severe osteoporosis, intellectual disability, and a high risk of premature vascular thrombosis (arterial and venous thromboembolism).

4. Maple Syrup Urine Disease (MSUD)

Etiology : Autosomal recessive deficiency of the branched-chain α \alpha α -keto acid dehydrogenase (BCKDH) complex.

Pathophysiology : Inability to degrade branched-chain amino acids ( Isoleucine, Leucine, Valine - ILV ). BCKDH is a multi-enzyme complex requiring 5 coenzymes: Thiamine (B1) , Lipoic acid, CoA (B5), FAD (B2), and NAD+ (B3).

Clinical Manifestations : Severe neurotoxicity (driven predominantly by toxic leucine accumulation), poor feeding, vomiting, hypertonia, seizures, and death in early infancy. Urine and sweat exhibit a distinct sweet maple syrup odor caused by α \alpha α -keto acid excretion. Treatment requires strict dietary BCAA restriction and thiamine supplementation in thiamine-responsive variants.

Diagnostic Summary Table

Disease Defective Enzyme Key Metabolite Accumulated Pathognomonic Clinical Features

OTC Deficiency Ornithine transcarbamylase Carbamoyl phosphate, Orotic acid Hyperammonemia, urine orotic acid, NO megaloblastic anemia, X-linked

PKU Phenylalanine hydroxylase / B H 4 BH_4 B H 4 ​ Phenylalanine, Phenylketones Musty odor, intellectual disability, hypopigmentation, fair hair/skin

Alkaptonuria Homogentisate oxidase Homogentisic acid Urine turns black on standing, ochronosis (cartilage dark), arthritis

Homocystinuria Cystathionine β \beta β -synthase (CBS) Homocysteine, Methionine Marfanoid habitus, downward lens subluxation, severe thrombosis risk

MSUD Branched-chain α \alpha α -keto acid dehydrogenase Leucine, Isoleucine, Valine Maple syrup urine odor, severe CNS degradation, ketoacidosis